China’s Fosun Pharma eyes spin-off listing of vaccine unit in hot Hong Kong IPO market

The board of Shanghai Fosun Pharmaceutical approved the spin-off and Hong Kong listing of its vaccine unit, aiming to bolster the business as biotechnology shares continue to outperform in the city’s stock market. The board cleared the proposed spin-off of Fosun Adgenvax (Chengdu) Biopharmaceutical for a Hong Kong initial public offering (IPO) on Thursday, according to a late filing by Fosun Pharma, whose shares are listed in Shanghai and Hong Kong. The filing did not disclose the planned IPO...